Phase 1

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Esperas) ESPS-001A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic CancerHirte, Dr HalOpen to recruitmentNCT02632448
(SignalChem) SLC-391-101A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of the Safety and Pharmacokinetics of the AXL Inhibitor SLC-391 Administered Orally to Subjects with Solid TumoursHotte, Dr SebastienOpen to recruitmentNCT03990454
(Alkermes) ALK4230-A101 / ARTISTRYA Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid TumorsHirte, Dr HalRecruitment on hold - COVID-19NCT02799095
(BMS) CA209848 / CheckMate 848A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or
Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High
Tumor Mutational Burden (TMB-H)
Hotte, Dr SebastienSuspended/On holdNCT03668119
(Fusion) FPX-01-01A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid TumoursJuergens, Dr RosalynSuspended/On holdNCT03746431
Download PDF